Literature DB >> 27743074

Well-Differentiated, Non-Functional, Non-Ampullary Duodenal Neuroendocrine Tumors: Toward Defining Evaluation and Management.

Timothy Weatherall1, Jason Denbo1, John Sharpe1, Michael Martin2,3, Thomas O'Brien4, Rajib Gupta5, Kenneth Groshart6, Stephen Behrman1, Paxton Dickson7.   

Abstract

INTRODUCTION: Nonfunctional, non-ampullary duodenal neuroendocrine tumors (dNETs) are rare neoplasms, and specific treatment recommendations are less clear than for other NETs.
MATERIALS AND METHODS: We performed a retrospective review of patients (pts) with a diagnosis of dNET, excluding hormonally functional, ampullary, and high-grade tumors. Clinical data were evaluated to identify factors that might impact clinical staging and predictors of metastases.
RESULTS: Thirty-six pts were identified. Surgical resection was performed in 28 and endoscopic resection in 8. LNs were included in specimens of 19/28 (68 %) pts who underwent surgical resection (median #LNs 5, range 1-12). Of these 19 pts, 5 (26 %) were found to be LN+. Of LN+ pts, all had tumors ≤2 cm. When compared to LN- pts, LN+ pts were more likely to have muscularis propria (MP) invasion (80 vs. 23 %, p = 0.04). Tumor size, tumor grade, lymphovascular invasion, and multifocality were similar between LN+ and LN- patients. No pt was found to have distant metastases. Heterogeneity in clinical staging modalities and small number of pts evaluated prohibited meaningful analysis of most appropriate preoperative imaging. At a median follow-up of 25 months (range 9-139), no patient developed recurrence or experienced disease-specific death.
CONCLUSIONS: Non-functional, non-ampullary dNETs, particularly those with MP invasion, have a propensity to metastasize to regional LNs. However, these neoplasms appear to have a favorable prognosis. Further evaluation of preoperative imaging is required to better determine most appropriate clinical staging. A suggested workup and management strategy for prospective evaluation is proposed.

Entities:  

Mesh:

Year:  2017        PMID: 27743074     DOI: 10.1007/s00268-016-3770-0

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  17 in total

1.  Duodenal carcinoid tumors: 5 cases treated by endoscopic submucosal dissection.

Authors:  Satohiro Matsumoto; Hiroyuki Miyatani; Yukio Yoshida; Mitsuhiro Nokubi
Journal:  Gastrointest Endosc       Date:  2011-09-23       Impact factor: 9.427

2.  Carcinoid tumors of the duodenum.

Authors:  John T Mullen; Huamin Wang; James C Yao; Jeffrey H Lee; Nancy D Perrier; Peter W T Pisters; Jeffrey E Lee; Douglas B Evans
Journal:  Surgery       Date:  2005-12       Impact factor: 3.982

3.  Neuroendocrine tumors, version 1.2015.

Authors:  Matthew H Kulke; Manisha H Shah; Al B Benson; Emily Bergsland; Jordan D Berlin; Lawrence S Blaszkowsky; Lyska Emerson; Paul F Engstrom; Paul Fanta; Thomas Giordano; Whitney S Goldner; Thorvardur R Halfdanarson; Martin J Heslin; Fouad Kandeel; Pamela L Kunz; Boris W Kuvshinoff; Christopher Lieu; Jeffrey F Moley; Gitonga Munene; Venu G Pillarisetty; Leonard Saltz; Julie Ann Sosa; Jonathan R Strosberg; Jean-Nicolas Vauthey; Christopher Wolfgang; James C Yao; Jennifer Burns; Deborah Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2015-01       Impact factor: 11.908

4.  Pathologic grade and tumor size are associated with recurrence-free survival in patients with duodenal neuroendocrine tumors.

Authors:  Brian R Untch; Keisha P Bonner; Kevin K Roggin; Diane Reidy-Lagunes; David S Klimstra; Mark A Schattner; Yuman Fong; Peter J Allen; Michael I D'Angelica; Ronald P DeMatteo; William R Jarnagin; T Peter Kingham; Laura H Tang
Journal:  J Gastrointest Surg       Date:  2014-01-22       Impact factor: 3.452

5.  Carcinoid tumors of the ampulla of Vater: a comparison with duodenal carcinoid tumors.

Authors:  H R Makhlouf; A P Burke; L H Sobin
Journal:  Cancer       Date:  1999-03-15       Impact factor: 6.860

Review 6.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

7.  Duodenal carcinoid tumors: how aggressive should we be?

Authors:  N J Zyromski; M L Kendrick; D M Nagorney; C S Grant; J H Donohue; M B Farnell; G B Thompson; D R Farley; M G Sarr
Journal:  J Gastrointest Surg       Date:  2001 Nov-Dec       Impact factor: 3.452

8.  Management strategy for small duodenal carcinoid tumors: does conservative management with close follow-up represent an alternative to endoscopic treatment?

Authors:  Byung-Hoon Min; Eun Ran Kim; Jun Haeng Lee; Kyoung-Mee Kim; Yang Won Min; Poong-Lyul Rhee; Jae J Kim; Jong Chul Rhee
Journal:  Digestion       Date:  2013-06-06       Impact factor: 3.216

9.  Endocrinocarcinomas (carcinoids and their variants) of the duodenum. An evaluation of 927 cases.

Authors:  J Soga
Journal:  J Exp Clin Cancer Res       Date:  2003-09

10.  Endoscopic management of a primary duodenal carcinoid tumor.

Authors:  Albin Abraham; Jaspreet Singh; Ghulam Siddiqui; Apsara Prasad; Sadat Rashid; Magdalene Vardaros; Vikas Garg; Kaleem Rizvon; Krishnaiyer Subramani; Paul Mustacchia
Journal:  Case Rep Gastroenterol       Date:  2012-05-23
View more
  2 in total

1.  Outcomes of Surgical and Endoscopic Resection of Duodenal Neuroendocrine Tumours (NETs): a Systematic Review of the Literature.

Authors:  Bobby V M Dasari; Sarah Al-Shakhshir; Timothy M Pawlik; Tahir Shah; Ravi Marudanayagam; Robert P Sutcliffe; Darius F Mirza; Paolo Muiesan; Keith J Roberts; John Isaac
Journal:  J Gastrointest Surg       Date:  2018-06-04       Impact factor: 3.452

2.  Patterns of Lymph Node Metastasis in Patients With T1/T2 Gastroduodenal Neuroendocrine Neoplasms: Implications for Endoscopic Treatment.

Authors:  Yu-Jie Zhou; Qi-Wen Wang; Qing-Wei Zhang; Jin-Nan Chen; Xin-Yuan Wang; Yun-Jie Gao; Xiao-Bo Li
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-28       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.